WeVote
Log In

Bill

Bill

AB 411

Relating to: creation of a farmland link program. (FE)

2025-2026 Regular Session Introduced by Elijah Behnke and 7 co-sponsors

Would allow a prescribing practitioner to request that a practice name, not the doctor’s, appears on labels for mifepristone or misoprostol, to protect clinicians from harassment w

Failed to concur in pursuant to Senate Joint Resolution 1
0
WeVote Research Nonpartisan
Bill Summary · AB 411

AB 411 — Summary (Prescription Drug Labeling for Mifepristone / Misoprostol)

Status: Vetoed by the Governor (veto date recorded 2025-06-05)
Introduced: (per docket) 2025 (user-provided date: Feb. 4, 2025)
Primary subject: Revises prescription labeling requirements for specific abortion medications

Purpose / Intent

AB 411 would have created a limited exception to Nevada’s standard prescription-labeling law to allow the prescribing practitioner for mifepristone, misoprostol, or their generic equivalents to request that the practitioner’s name on the dispensed label be replaced with the name of the prescribing health care practice. The stated policy purpose in testimony supporting the bill was to protect clinicians who provide medication abortion from harassment, threats, or other retaliation while maintaining medication access.

Key provisions

  • Amends NRS 639.2801 (prescription label requirements).
  • For prescriptions of mifepristone, misoprostol, or their generic alternatives, an affixed label or device on the dispensed container:
    • May (Senate Amendment No. 585 changed mandatory language to permissive) include the name of the prescribing health care practice instead of the prescribing practitioner’s name, upon the practitioner’s request.
  • All other standard label requirements remain in place, including date, practitioner name/address/serial number (where applicable), patient name, quantity, directions, expiration, drug name and strength, and a standard cautionary warning.
  • Committee reports indicate no fiscal impact to state or local government.

Who would be affected

  • Prescribing practitioners and health care practices: gives an option to request anonymity on the dispensed label for the two specified drugs.
  • Pharmacies and pharmacists: required to honor practitioner requests when filling these prescriptions and to apply the practice name on the label.
  • Patients: would receive labels that could show a practice name instead of an individual clinician’s name.
  • Emergency and urgent care providers: potentially affected by reduced immediate access to the prescribing clinician’s identity on a patient’s medication label.
  • Clinics and reproductive health providers: would gain a tool aimed at reducing exposure of individual providers.

Stakeholder reactions / potential impacts

  • Supporters argued the change protects clinicians from harassment and preserves access to care in a contentious environment.
  • Opponents raised concerns about patient safety, medical accountability, and potential impediments to emergency care—pointing to public testimony asserting that removing a prescriber’s name might delay contact with the clinician in adverse events.
  • No fiscal effects reported.

Legislative / procedural notes

  • The bill moved through relevant committees (Health & Human Services; Commerce & Labor) and was amended (notably Senate Amendment No. 585 changing "must" to "may").
  • The enrolled bill was delivered to the Governor and subsequently recorded as vetoed on June 5, 2025.

If you want, I can provide (1) the full redline of the NRS change proposed by AB 411, (2) a timeline of committee actions and votes, or (3) a brief compare/contrast of how other states handle prescriber-identification on prescription labels for medication abortion.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.